{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-23-001826","form_type":"8-K","ticker":"ACRS","cik":"0001557746","company_name":"Aclaris Therapeutics, Inc.","filed_at":"2023-02-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:45.561304+00:00","generated_at":"2026-06-19T02:35:39.308639+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Aclaris Q4 net loss $27.6M; revenue $7.8M on licensing; cash $229.8M through 2025","bullets":["Q4 2022 net loss $27.6M vs $22.8M in Q4 2021; full-year net loss $86.9M vs $90.9M.","Q4 total revenue $7.8M (incl. $6.7M licensing, $5M from Pediatrix) vs $1.5M prior year.","Cash, equivalents and marketable securities $229.8M; expected to fund operations through end of 2025.","Phase 2a zunsemetinib HS topline data expected March 2023; Phase 2b RA data H2 2023.","Phase 2b ATI-1777 atopic dermatitis topline data mid-2023; Phase 1 MAD ATI-2138 data H2 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-23-001826","json":"https://secwatch.observer/filing/0001558370-23-001826.json","markdown":"https://secwatch.observer/filing/0001558370-23-001826.md","text":"https://secwatch.observer/filing/0001558370-23-001826.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023001826/0001558370-23-001826-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1557746/000155837023001826/acrs-20230223x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T02:35:39.308639+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}